XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Revenues
3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
The following table presents a summary of total revenues (in thousands): 
Three Months Ended
March 31,
20222021
Xyrem$247,497 $335,550 
Xywav186,080 75,416 
   Total Oxybate433,577 410,966 
Epidiolex/Epidyolex157,893 — 
Sunosi15,878 11,606 
Sativex4,742 — 
Total Neuroscience612,090 422,572 
Zepzelca59,338 54,334 
Rylaze54,220 — 
Vyxeos33,757 33,155 
Defitelio/defibrotide 49,489 49,619 
Erwinaze/Erwinase— 41,068 
Total Oncology196,804 178,176 
Other943 2,783 
Product sales, net809,837 603,531 
Royalties and contract revenues3,884 4,050 
Total revenues$813,721 $607,581 
The following table presents a summary of total revenues attributed to geographic sources (in thousands): 
Three Months Ended
March 31,
20222021
United States$740,583 $548,292 
Europe61,028 47,233 
All other12,110 12,056 
Total revenues$813,721 $607,581 
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 
Three Months Ended
March 31,
20222021
ESSDS55 %67 %
McKesson12 %14 %
Financing and payment
Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 45 days.
Contract Liabilities - Deferred Revenue
The deferred revenue balance as of March 31, 2022 primarily related to deferred upfront fees received from Nippon Shinyaku Co., Ltd., or Nippon Shinyaku, in connection with two license, development and commercialization agreements granting Nippon Shinyaku exclusive rights to develop and commercialize each of Defitelio and Vyxeos in Japan. We recognized contract revenues of $0.5 million during the three months ended March 31, 2022, relating to these upfront payments.
The deferred revenue balances are being recognized over an average of four years representing the period over which we expect to perform our research and developments obligations under each agreement.
The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the three months ended March 31, 2022 (in thousands): 
Contract Liabilities
Balance as of December 31, 2021$2,556 
Amount recognized within royalties and contract revenues(523)
Balance as of March 31, 2022$2,033